Novo Nordisk has profited from diabetic treatment price hikes despite decreasing manufacturing costs
An estimated 34.2 million Americans have diabetes, of which 7.4 million require insulin regularly to survive4,1. Despite the vital need for the medicine, it is among the costliest traditional treatments in the US2. According to a study, insulin pr...
Register to read the full analysis —or— Upgrade to access more features
#cost
#price
#pricing
#returns
Actual Direct Impact
Assess the impact materiality of this Topic for Novo Nordisk
How negative/positive is the impact of Novo Nordisk for this Topic?
Share this Analysis
Keen to rectify an issue with this analysis?
Report issue
There is no comment yet.